Document Detail

Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
MedLine Citation:
PMID:  2260619     Owner:  NLM     Status:  MEDLINE    
Therapy with recombinant human erythropoietin (rHuEPO) can reverse anemia and improve the quality of life in anemic hemodialysis patients. However, therapy is costly and must be used efficiently. An initial rHuEPO dose less than 50 U/kg intravenously three times weekly may be adequate to achieve a hematocrit of 30-33% in many patients. Acquired iron deficiency is a common problem during rHuEPO therapy and must be prevented with oral and parenteral iron replacement to maintain the efficacy of rHuEPO. Patients should be monitored carefully for additional problems including: an increase in blood pressure; onset of seizures or headaches; increased blood potassium, phosphate, and creatinine concentrations; enhanced coagulability resulting in dialyzer and vascular access clotting; and myalgias with a 'flu-like' syndrome.
P A Abraham
Related Documents :
18446719 - Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in ...
17828809 - Stimulating erythropoiesis in inflammatory bowel disease associated anemia.
1680449 - Experience with subcutaneous erythropoietin in capd patients.
18581199 - Japanese epidemiological survey with consensus statement on japanese guidelines for tre...
21040319 - A rapid infusion protocol is safe for total dose iron polymaltose: time for change.
7004809 - Effect of portacaval anastomosis on hypersplenism.
22233329 - The pathology and clinical features of early recurrent membranous glomerulonephritis.
24008429 - Effect of using ultrapure dialysate for hemodialysis on the level of circulating bacter...
11721299 - Pattern of sensory conduction in guillain-barre syndrome.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of nephrology     Volume:  10 Suppl 2     ISSN:  0250-8095     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  1990  
Date Detail:
Created Date:  1991-01-31     Completed Date:  1991-01-31     Revised Date:  2007-02-14    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  7-14     Citation Subset:  IM    
Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  etiology,  physiopathology,  therapy*
Blood Pressure
Erythropoietin / administration & dosage,  adverse effects,  therapeutic use*
Headache / etiology
Iron / deficiency
Kidney Failure, Chronic / complications*
Recombinant Proteins
Seizures / etiology
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Implications of recombinant erythropoietin therapy for renal transplantation.
Next Document:  Warner-Lambert/Parke-Davis Award lecture. Pathobiology of the intestinal epithelial barrier.